A pre-specified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (dapa-ckd) randomized controlled trial on the incidence of abrupt declines in kidney function

HIGHLIGHTS

• who: Hiddo J.L. Heerspink from the Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Centre Groningen, Groningen, the College London, London, UK have published the Article: A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function, in the Journal: (JOURNAL) of 19/04/2021
• what: In this analysis, the authors report the effect of dapagliflozin on abrupt declines in kidney function. The primary pre-specified outcome of the current analysis was . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.